Tirzepatide Could Supercharge Weight Loss And Block Tumors.

A mouse study presented at ENDO 2025 by University of Michigan researchers found that tirzepatide (marketed as Mounjaro/Zepbound) caused ~20% weight loss in obese mice and dramatically slowed breast tumor growth, linking fat loss directly to improved cancer outcomes.

Meanwhile, a real-world analysis by Mayo Clinic (120 postmenopausal women over ~18 months) showed that combining tirzepatide with menopause hormone therapy boosted results even further—17% average body weight loss vs. 14% without hormones, with nearly half losing 20%+ of their weight.

If you’re a postmenopausal woman struggling with obesity, this combo could be worth discussing with your doctor—tirzepatide already works wonders alone, and when paired with hormone therapy it might unlock your best results yet.